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Epidemiological changes with potential implication for antifungal prescription
recommendations for fungaemia: data from a nationwide fungaemia surveillance programme
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Abstract
Significant changes in the management of fungaemia have occurred over the last decade with increased use of fluconazole prophylaxis, of
empirical treatment and of echinocandins as first-line agents for documented disease. These changes may impact the epidemiology of
fungaemia. We present nationwide data for Denmark from 2010 to 2011. A total of 1081 isolates from 1047 episodes were recorded in 995
patients. The numbers of patients, episodes and recovered isolates increased by 13.1%, 14.5% and 14.1%, respectively, from 2010 to 2011.
The incidence rate was significantly higher in 2011 (10.05/100 000) than in 2010 (8.82/100 000), but remained constant in the age groups 0–
79 years. The incidence rate was highest at the extremes of age and in males. Candida albicans accounted for 52.1% but declined during
2004–11 (p 0.0155). Candida glabrata accounted for 28% and increased during 2004–2011 (p <0.0001). Candida krusei, Candida tropicalis and
Candida parapsilosis remained rare (3.3–4.2%). The species distribution changed with increasing age (fewer C. parapsilosis and more
C. glabrata) and by study centre. Overall, the susceptibility rates were: amphotericin B 97.3%, anidulafungin 93.8%, fluconazole 66.7%,
itraconazole 69.6%, posaconazole 64.2% and voriconazole 85.0%. Acquired echinocandin resistance was molecularly confirmed in three
isolates. The use of systemic antifungals doubled over the last decade (2002–2011) (from 717 000 to 1 450 000 defined daily doses/year) of
which the vast majority (96.9%) were azoles. The incidence of fungaemia continues to increase in Denmark and is associated with a
decreasing proportion being susceptible to fluconazole. Changes in demography, higher incidence in the elderly and higher antifungal
consumption can at least in part explain the changes.
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